Fig. 1

Expression and prognostic value of YTHDF2 in glioma. A–C The mRNA expression of YTHDF2 in primary gliomas with different WHO grade (A), IDH-mutant status (B), and classifications in CGGA microarray cohort. *P < 0.05; **P < 0.01; ****P < 0.0001. (D) The mRNA expression of YTHDF2 in primary and recurrent gliomas in CGGA microarray cohort. *P < 0.05. E–H The mRNA expression of YTHDF2 in gliomas stratified by different clinicopathological features in CGGA RNA-seq cohort (n = 693). **P < 0.01; ***P < 0.001; ****P < 0.0001. I Representative immunohistochemistry images of YTHDF2 protein in gliomas with different IDH status and histological grades. Bar = 50 µm. J The semi-quantitative for the immunohistochemistry results of YTHDF2 proteins. ***P < 0.001; ****P < 0.0001. K The protein expression of YTHDF2 in IDH-wildtype gliomas and in vitro cell models with different histological grades. L The protein expression of YTHDF2 in IDH-mutant gliomas with different histological grade. M–P Kaplan–Meier curves of gliomas and GBM from CGGA microarray cohort (M, N) and CGGA RNA-seq cohort (O, P) stratified by YTHDF2 expression. Q Venn diagram shows the overlap genes whose expression is positively correlated with YTHDF2 expression in primary gliomas form different datasets. R GO analysis terms of the 1493 genes whose expression are positively correlated with YTHDF2 expression in primary gliomas from four datasets